One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
An Opportune Time for Newborn Screening in Duchenne Muscular Dystrophy
Stephen M. Chrzanowski, MD, PhD1; Meghan M. McAnally, MD, MPH1; Peter B. Kang, MD2,3
doi : 10.1001/jamaneurol.2021.1782
JAMA Neurol. 2021;78(8):901-902
Advanced Practice Clinicians—Neurology’s Underused Resource
Calli L. Cook, DNP1; Heidi B. Schwarz, MD2
doi : 10.1001/jamaneurol.2021.1416
JAMA Neurol. 2021;78(8):903-904
Sailing to the Mediterranean and Navigating Amyotrophic Lateral Sclerosis
Christina L. Roland, MD, MS1
doi : 10.1001/jamaneurol.2021.1652
JAMA Neurol. 2021;78(8):905-906
Equity and the JAMA Network
Phil B. Fontanarosa, MD, MBA1; Annette Flanagin, RN, MA2; John Z. Ayanian, MD, MPP3,4; Robert O. Bonow, MD, MS5,6; Neil M. Bressler, MD7,8; Dimitri Christakis, MD, MPH9,10; Mary L. Disis, MD11,12; S. Andrew Josephson, MD13,14; Melina R. Kibbe, MD15,16; Dost Öngür, MD, PhD17,18; Jay F. Piccirillo, MD19,20; Rita F. Redberg, MD, MPH21,22; Frederick P. Rivara, MD, MPH23,24; Kanade Shinkai, MD, PhD25,26; Clyde W. Yancy, MD, MSc27,28
doi : 10.1001/jamaneurol.2021.2135
JAMA Neurol. 2021;78(8):1-3
Streamlining the Path to Endovascular Reperfusion in Stroke
Bruce C. V. Campbell, MBBS(Hons), BMedSc, PhD1,2
doi : 10.1001/jamaneurol.2021.1369
JAMA Neurol. 2021;78(8):909-911
Association of Fetal Exposure to Newer Antiseizure Medications With Neurodevelopment
Torbjörn Tomson, MD, PhD1; Rebecca Bromley, ClinPsyD, PhD2,3
doi : 10.1001/jamaneurol.2021.1217
JAMA Neurol. 2021;78(8):911-913
APOE ?4 Association With Cognition and Alzheimer Disease Biomarkers in Down Syndrome—Implications for Clinical Trials and Treatments for All
Cynthia A. Lemere, PhD1; Elizabeth Head, PhD2; David M. Holtzman, MD3
doi : 10.1001/jamaneurol.2021.1649
JAMA Neurol. 2021;78(8):913-915
Direct to Angiography vs Repeated Imaging Approaches in Transferred Patients Undergoing Endovascular Thrombectomy
Amrou Sarraj, MD1; Nitin Goyal, MD2,3; Michael Chen, MD4; James C. Grotta, MD5; Spiros Blackburn, MD6; Manuel Requena, MD7; Haris Kamal, MD8; Michael G. Abraham, MD9; Lucas Elijovich, MD2,3; Mark Dannenbaum, MD6; Osman Mir, MD10; Wondwossen G. Tekle, MD11; Deep Pujara, MBBS, MPH1; Faris Shaker, MBChB1; Chunyan Cai, PhD12; Laith Maali, MD9; Yazan Radaideh, MD4; Sujan Teegala Reddy, MD13; Kaushik Niranjan Parsha, MD3; Bader Alenzi, MD14; Mohammad Ammar Abdulrazzak, MD1; Jonathan Greco, DO1; Daniel Hoit, MD3; Sheryl B. Martin-Schild, MD15; Sarah Song, MD, MPH4; Clark Sitton, MD16; Georgios K. Tsivgoulis, MD2,17; Andrei V. Alexandrov, MD2; Adam S. Arthur, MD, MPH2,3; Arthur L. Day, MD6; Ameer E. Hassan, DO11; Marc Ribo, MD7
doi : 10.1001/jamaneurol.2021.1707
JAMA Neurol. 2021;78(8):916-926
A direct to angiography (DTA) treatment paradigm without repeated imaging for transferred patients with large vessel occlusion (LVO) may reduce time to endovascular thrombectomy (EVT). Whether DTA is safe and associated with better outcomes in the late (>6 hours) window is unknown. Also, DTA feasibility and effectiveness in reducing time to EVT during on-call vs regular-work hours and the association of interfacility transfer times with DTA outcomes have not been established.
Two-Year-Old Cognitive Outcomes in Children of Pregnant Women With Epilepsy in the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs Study
Kimford J. Meador, MD1; Morris J. Cohen, EdD2; David W. Loring, PhD3; Ryan C. May, PhD4; Carrie Brown, MS4; Chelsea P. Robalino, MStat4; Abigail G. Matthews, PhD4; Laura A. Kalayjian, MD5; Elizabeth E. Gerard, MD6; Evan R. Gedzelman, MD3; Patricia E. Penovich, MD7; Jennifer Cavitt, MD8; Sean Hwang, MD9; Maria Sam, MD10; Alison M. Pack, MD11; Jacqueline French, MD12; Jeffrey J. Tsai, MD13; Page B. Pennell, MD14; for the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs Investigator Group
doi : 10.1001/jamaneurol.2021.1583
JAMA Neurol. 2021;78(8):927-936
The neurodevelopmental risks of fetal exposure are uncertain for many antiseizure medications (ASMs).
Association of Apolipoprotein E ?4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome
Alexandre Bejanin, PhD1,2; Maria Florencia Iulita, PhD1,2; Eduard Vilaplana, PhD1,2; Maria Carmona-Iragui, MD, PhD1,2,3; Bessy Benejam, MSc3; Laura Videla, MSc1,2,3; Isabel Barroeta, MD, PhD1,2; Susana Fernandez, MD1; Miren Altuna, MD, PhD1,2; Jordi Pegueroles, MSc1,2; Victor Montal, MSc1,2; Silvia Valldeneu, MSc1,2; Sandra Giménez, MD, PhD4; Sofía González-Ortiz, MD, PhD5; Laia Muñoz, BSc1,2; Concepción Padilla, PhD1,2; Mateus Rozalem Aranha, MD1,2; Teresa Estellés, MD1,2; Ignacio Illán-Gala, MD, PhD1,2; Olivia Belbin, PhD1,2; Valle Camacho, MD, PhD6; Liam Reese Wilson, PhD7; Tiina Annus, PhD7; Ricardo S. Osorio, MD8; Sebastián Videla, MD, PhD9; Sylvain Lehmann, MD, PhD10; Anthony J. Holland, MD7; Henrik Zetterberg, MD, PhD11,12,13,14; Kaj Blennow, MD, PhD11,12; Daniel Alcolea, MD, PhD1,2; Jordi Clarimon, PhD1,2; Shahid H. Zaman, MD, PhD7,15; Rafael Blesa, MD, PhD1,2; Alberto Lleó, MD, PhD1,2; Juan Fortea, MD, PhD1,2,3
doi : 10.1001/jamaneurol.2021.1893
JAMA Neurol. 2021;78(8):937-947
Alzheimer disease (AD) is the leading cause of death in individuals with Down syndrome (DS). Previous studies have suggested that the APOE ?4 allele plays a role in the risk and age at onset of dementia in DS; however, data on in vivo biomarkers remain scarce.
Association Between SARS-CoV-2 Infection and Immune-Mediated Myopathy in Patients Who Have Died
Tom Aschman, MD1; Julia Schneider, MSc2; Selina Greuel, MD3; Jenny Meinhardt, MD1; Simon Streit, MD1; Hans-Hilmar Goebel, MD1; Ivana Büttnerova, MD4; Sefer Elezkurtaj, MD3; Franziska Scheibe, MD5; Josefine Radke, MD1; Christian Meisel, MD6; Christian Drosten, MD2; Helena Radbruch, MD1; Frank L. Heppner, MD1,7,8,9; Victor Max Corman, MD2; Werner Stenzel, MD1,10
doi : 10.1001/jamaneurol.2021.2004
JAMA Neurol. 2021;78(8):948-960
Myalgia, increased levels of creatine kinase, and persistent muscle weakness have been reported in patients with COVID-19.
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease
Rik Ossenkoppele, PhD1,2; Ruben Smith, MD, PhD1; Niklas Mattsson-Carlgren, MD, PhD1,3,4; Colin Groot, PhD2; Antoine Leuzy, PhD1; Olof Strandberg, PhD1; Sebastian Palmqvist, MD, PhD1; Tomas Olsson, PhD5; Jonas Jögi, MD, PhD6; Erik Stormrud, MD, PhD1,7; Hanna Cho, MD8; Young Hoon Ryu, MD, PhD9; Jae Yong Choi, PhD9,10; Adam L. Boxer, MD, PhD11; Maria L. Gorno-Tempini, MD, PhD11; Bruce L. Miller, MD11; David Soleimani-Meigooni, MD11; Leonardo Iaccarino, PhD11; Renaud La Joie, PhD11; Suzanne Baker, PhD12; Edilio Borroni, PhD13; Gregory Klein, PhD13; Michael J. Pontecorvo, PhD14; Michael D. Devous Sr, PhD14; William J. Jagust, MD12,15; Chul Hyoung Lyoo, MD, PhD8; Gil D. Rabinovici, MD, PhD11,16,17,18; Oskar Hansson, MD, PhD1,7
doi : 10.1001/jamaneurol.2021.1858
JAMA Neurol. 2021;78(8):961-971
Tau positron emission tomography (PET) tracers have proven useful for the differential diagnosis of dementia, but their utility for predicting cognitive change is unclear.
Home Health Management of Parkinson Disease Deep Brain Stimulation
Gordon Duffley, PhD1,2; Barbara J. Lutz, PhD3; Aniko Szabo, PhD4; Adrienne Wright, RN5; Christopher W. Hess, MD5; Adolfo Ramirez-Zamora, MD5; Pamela Zeilman, ARNP5; Shannon Chiu, MD5; Kelly D. Foote, MD5; Michael S. Okun, MD5; Christopher R. Butson, PhD1,2,5,6
doi : 10.1001/jamaneurol.2021.1910
JAMA Neurol. 2021;78(8):972-981
The travel required to receive deep brain stimulation (DBS) programming causes substantial burden on patients and limits who can access DBS therapy.
Functional Outcomes Over the First Year After Moderate to Severe Traumatic Brain Injury in the Prospective, Longitudinal TRACK-TBI Study
Michael A. McCrea, PhD1; Joseph T. Giacino, PhD2,3,4; Jason Barber, MS5; Nancy R. Temkin, PhD5; Lindsay D. Nelson, PhD1; Harvey S. Levin, PhD6; Sureyya Dikmen, PhD5; Murray Stein, MD, PhD7; Yelena G. Bodien, PhD2,3,4; Kim Boase, BA5; Sabrina R. Taylor, PhD8; Mary Vassar, RN, MS8; Pratik Mukherjee, MD, PhD8; Claudia Robertson, MD6; Ramon Diaz-Arrastia, MD, PhD9; David O. Okonkwo, MD, PhD10; Amy J. Markowitz, JD8; Geoffrey T. Manley, MD, PhD8; and the TRACK-TBI Investigators
doi : 10.1001/jamaneurol.2021.2043
JAMA Neurol. 2021;78(8):982-992
Moderate to severe traumatic brain injury (msTBI) is a major cause of death and disability in the US and worldwide. Few studies have enabled prospective, longitudinal outcome data collection from the acute to chronic phases of recovery after msTBI.
DIAPH1 Variants in Non–East Asian Patients With Sporadic Moyamoya Disease
Adam J. Kundishora, MD1; Samuel T. Peters, BS2; Amélie Pinard, PhD1; Daniel Duran, MD2; Shreyas Panchagnula, BS3; Tanyeri Barak, MD3,4,5,6; Danielle F. Miyagishima, BA3,4,5,6; Weilai Dong, BS4,7; Hannah Smith, BS1; Jack Ocken, BA1; Ashley Dunbar, MD3; Carol Nelson-Williams, MS4; Shozeb Haider, PhD8; Rebecca L. Walker, PhD9; Boyang Li, MS10; Hongyu Zhao, PhD10; Dean Thumkeo, MD11; Arnaud Marlier, PhD3; Phan Q. Duy, BS1; Nicholas S. Diab, BA3,4; Benjamin C. Reeves, BA1; Stephanie M. Robert, MD, PhD3; Nanthiya Sujijantarat, MD3; Amber N. Stratman, PhD12; Yi-Hsien Chen, PhD13; Shujuan Zhao, BS13; Isabelle Roszko, PhD14; Qiongshi Lu, PhD15; Bo Zhang, PhD14; Shrikant Mane, PhD16; Christopher Castaldi, MS16; Francesc López-Giráldez, PhD16; James R. Knight, PhD16; Michael J. Bamshad, MD17; Deborah A. Nickerson, PhD17; Daniel H. Geschwind, MD, PhD18; Shih-Shan Lang Chen, MD19; Phillip B. Storm, MD19; Michael L. Diluna, MD3; Charles C. Matouk, MD3; Darren B. Orbach, MD, PhD20; Seth L. Alper, MD, PhD21; Edward R. Smith, MD20; Richard P. Lifton, MD, PhD4,7; Murat Gunel, MD3,4; Dianna M. Milewicz, MD, PhD1; Sheng Chih Jin, PhD13; Kristopher T. Kahle, MD, PhD3,22,23
doi : 10.1001/jamaneurol.2021.1681
JAMA Neurol. 2021;78(8):993-1003
Moyamoya disease (MMD), a progressive vasculopathy leading to narrowing and ultimate occlusion of the intracranial internal carotid arteries, is a cause of childhood stroke. The cause of MMD is poorly understood, but genetic factors play a role. Several familial forms of MMD have been identified, but the cause of most cases remains elusive, especially among non–East Asian individuals.
Association Between Globular Glial Tauopathies and Frontotemporal Dementia—Expanding the Spectrum of Gliocentric Disorders
Shelley L. Forrest, PhD1,2; Jillian J. Kril, PhD1,2; Gabor G. Kovacs, MD, PhD3,4,5,6
doi : 10.1001/jamaneurol.2021.1813
JAMA Neurol. 2021;78(8):1004-1014
Globular glial tauopathies (GGTs), as defined by a consensus study in 2013, belong to the group of frontotemporal lobar degenerations and expand the spectrum of glial-predominant neurodegenerative diseases. Three neuropathological subtypes of GGT (types I-III) are characterized by phosphorylated tau-immunopositive inclusions that are predominantly in oligodendroglia and/or astroglia in the frontal, temporal, and/or precentral cortices. Type II is largely restricted to the corticospinal system. The low incidence of GGT (<10% of cases of frontotemporal lobar degeneration with tau pathology), together with its unusual combination of neuronal and nonneuronal pathology, has hindered identification and accurate diagnosis. This review collated clinical, demographic, neuropathological, and genetic data from 88 published GGT cases identified on PubMed to examine the association between GGT and frontotemporal dementia and associated disorders.
Dynamic Tremor in a Patient With Parkinson Disease
Carina França, MD, PhD1,2; Kleber Paiva Duarte, MD1; Rubens Gisbert Cury, MD, PhD1,2
doi : 10.1001/jamaneurol.2021.1431
JAMA Neurol. 2021;78(8):1015
Ondine’s Curse and Trismus in Association With Kelch-like Protein-11 Autoimmunity
Michelle F. Devine, MD1,2,3; Peter C. Gay, MD1,4,5; Divyanshu Dubey, MD2,6
doi : 10.1001/jamaneurol.2021.1557
JAMA Neurol. 2021;78(8):1016-1017
Progressive Ataxia and Downbeat Nystagmus in an Adult
Alejandra Collía Fernández, MD1; Begoña Huete Antón, MD1; Juan Carlos García-Moncó, MD, PhD1
doi : 10.1001/jamaneurol.2021.1205
JAMA Neurol. 2021;78(8):1018-1019
Questions on Predicting Early Neurological Deterioration in Patients With Minor Stroke and Large-Vessel Occlusion
Johanna M. Ospel, MD1,2; Bijoy K. Menon, MD1; Mayank Goyal, MD, PhD1,3,4
doi : 10.1001/jamaneurol.2021.2022
JAMA Neurol. 2021;78(8):1020
Questions on Predicting Early Neurological Deterioration in Patients With Minor Stroke and Large-Vessel Occlusion—Reply
Pierre Seners, MD, PhD1,2; Jean-Claude Baron, MD, ScD1; Guillaume Turc, MD, PhD1
doi : 10.1001/jamaneurol.2021.2025
JAMA Neurol. 2021;78(8):1020-1021
